Other trials seeking to target BCL11A and HbF expression include Bioray’s Phase 1/2 trial in Shanghai for TDT (NCT04211480), Editas’ Ruby trial testing EDIT-301 for SCD (NCT04853576), Novartis Pharmaceuticals testing OTQ923 and HIX763 for SCD (NCT04443907), Sangamo Therapeutics testing ST-400 for TDT (NCT03432364), and Sanofi’s PRECIZN-1 trial testing SAR445136 (BIVV003) for SCD (NCT03653247). The gene discussed is SCD; the disease is Schnyder corneal dystrophy.